|Description||AZD 8186 is a selective PI3Kβ/δ inhibitor (IC50= 0.003 μM for PI3Kβ, and 0.017 μM for PI3Kδ) with potential antineoplastic activity. It shows no significant binding against a panel of 442 other kinases when tested at a concentration of 10 µM and exhibits high oral efficacy in mouse cancer models.|
|Synonyms||(R)-8-(1-((3,5-difluorophenyl)amino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide; AZD8186; AZD 8186; AZD-8186.|
|Storage||Store in a cool and dry place (or refer to the Certificate of Analysis).|
|Boiling Point||645.2±55.0 °C at 760 Torr|
AMG319 is a potent and selective PI3Kδ inhibitor with IC50 of 18 nM, >47-fold selectivity over other PI3Ks. Phase 2.
PI3Ky inhibitor 1
PI3Ky inhibitor 1 is a potent PI3Ky inhibitor.
GSK2292767 is a Phosphatidylinositol 3 kinase delta inhibitor applicated for the treatment of respiratory diseases including asthma and COPD in clinical trials....
MLN1117, also known as INK1117, is a PI3Kα inhibitor which could lead to the apoptosis and growth retardation of tumor cells expressed by PI3Kα. IC50: 15 nM.
CZC24832 is the first selective inhibitor of phosphoinositide 3-kinase γ (PI3Kγ) with efficacy in in vitro and in vivo models of inflammation. Extensive target-...
Pilaralisib, also known as XL147, is a methylbenzenesulfonamide derivative that reversibly inhibits class I PI3Ks (IC50s = 39, 36, 23, and 383 nM for p110α, δ, ...
Seletalisib is a selective Phosphatidylinositol 3 kinase delta inhibitor originated by UCB.It is a Immunomodulator. Phaes I clinical trials for Plaque psoriasis...
LY3023414, a quinoline derivative, has been found to be a PI3Kα and mTOR inhibitor that could influence cell proliferation and cycle of tumor cells. It was just...
GDC-0941 dimethanesulfonate is a potent inhibitor of PI3Kα/δ with modest selectivity against p110β and p110γ. It is a novel selective class I phosphatidylinosit...
PQR309, a pan inhibitor of phosphoinositide-3-kinases, is still under Phase II clinical trial against Glioblastoma and Lymphoma.
A selective class I PI3K inhibitor; it inhibits PI3K p110 isoforms, mTOC1 and also DNA-PK; a valuable tool compound
Taselisib, also known as GDC0032 or RG7606, is a selective, potent, orally bioavailable inhibitor of PI3Ka with a Ki = 0.2nM, and with reduced inhibitory activi...
AZD6482 is a PI3Kβ inhibitor with IC50 of 10 nM, 8-, 87- and 109-fold more selective to PI3Kβ than PI3Kδ, PI3Kα and PI3Kγ. Phase 1.
Pilaralisib is a Class 1 phosphatidylinositol 3 kinase (PI3K) family inhibitor. It is an orally bioavailable small molecule, targeting the class I PI3K family o...
PQR530 is a potent dual pan PI3K/mTOR inhibitor undergoing phase II clinical trials in 2016. Aberrant activation of the PI3K/mTOR signaling pathway promotes the...
740 Y-P is a cell-permeable phosphopeptide activator of PI3K. It binds to the p85 N- and C-terminal SH2 domains of PI3K but not to GST or the N-terminal domain ...
PI3Kα/mTOR-IN-1 is a potent dual inhibitor of PI3Kα/mTOR (Kis= 10.6 nM and 12.5 nM for mTOR and PI3Kα, respectively).
Vps34-PIK-III is a potent and selective inhibitor of the type 3 phosphatidylinositol 3-kinase (PI3K) vacuolar protein sorting 34 (Vps34) (IC50= 18 nM). Vps34-PI...
1,3-Dicaffeoylquinic acid, a caffeoylquinic acid derivative found in artichoke, acts as an anti-hyperlipidemic agent and activates PI3K/Akt.
PI3Kδ-IN-2 is a potent and selective inhibitor ofPI3Kδ (IC50= 6.4 M).